Humant serumalbumin (I-125) Amersham Health 8-22 MBq/ml Injektionsvätska, lösning Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

humant serumalbumin (i-125) amersham health 8-22 mbq/ml injektionsvätska, lösning

ge healthcare as - albumin, joderat (i-125) humant - injektionsvätska, lösning - 8-22 mbq/ml - albumin, joderat (i-125) humant 8 - 22 mbq aktiv substans; bensylalkohol hjälpämne - humant jod(i-125)albumin

Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech

xbiotech germany gmbh - humant iggl monoklonal antikropp specifik för human interleukin-1 alfa - kolorektala neoplasmer - antineoplastiska medel - behandling av metastaserad kolorektal cancer.

Shingrix Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

shingrix

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - bältros (herpes zoster) - vacciner - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. användning av shingrix bör ske i enlighet med officiella rekommendationer.

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vacciner - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influensavirus (levande dämpad) av följande stam: a / vietnam / 1203/2004 (h5n1) stam - influensa, människa - vacciner - profylax av influensa i en officiellt deklarerad pandemisk situation hos barn och ungdomar från 12 månader till yngre än 18 år. pandemic influenza vaccine h5n1 astrazeneca bör användas i enlighet med officiella riktlinjer.

Jcovden (previously COVID-19 Vaccine Janssen) Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vacciner - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Celvapan Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

celvapan

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vacciner - profylax av influensa orsakad av a (h1n1) v 2009 virus. celvapan bör användas i enlighet med officiella riktlinjer.

Pandemic Influenza Vaccine H5N1 Baxter AG Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 baxter ag

resilience biomanufacturing ireland limited - influensavaccin (helvirion, inaktiverad) innehållande antigen av: a / vietnam / 1203/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vacciner - profylax av influensa i en officiellt deklarerad pandemisk situation. pandemiskt influensavaccin ska användas enligt officiell vägledning.

Pumarix Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

pumarix

glaxosmithkline biologicals s.a.  - pandemic influenza vaccine (h5n1) (split virion, inaktiverat, med adjuvans) - influenza, human; immunization; disease outbreaks - vacciner - profylax av influensa i en officiellt deklarerad pandemisk situation. pandemi-influensa-vaccinet bör användas i enlighet med officiella riktlinjer.

Spikevax (previously COVID-19 Vaccine Moderna) Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.